ORIC Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated January 9, 2023. The filing reports a corporate update, anticipated 2023 milestones, and the company’s planned participation in the 41st Annual J.P. Morgan Healthcare Conference. The filing does not cover a specific quarterly or annual financial reporting period.
Financial Metrics and Condition
The filing text does not provide clear values for revenue, profit or loss, cash flow, operating margins, debt, cash, liquidity, or other financial metrics. Item 2.02 incorporates the Regulation FD disclosure in Item 7.01, but the referenced press release is not included in the provided source text.
Material Changes Versus Prior Comparable Period
The filing does not provide financial-period comparisons or quantify material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
- The company announced anticipated milestones for 2023, but the specific milestones are not included in the provided filing text.
- The company announced participation in the 41st Annual J.P. Morgan Healthcare Conference.
- The filing does not provide specific guidance, risk disclosures, contingencies, or unusual accounting items.
- The information was furnished under Regulation FD and is expressly stated not to be deemed filed for purposes of Section 18 of the Exchange Act, except as otherwise expressly incorporated.
Key Facts for Investors to Verify
- Review Exhibit 99.1 for the detailed corporate update and 2023 milestone calendar.
- Verify any cash runway, financing needs, clinical development updates, or other financial information disclosed in the press release.
- Confirm the company’s planned activities and presentation details for the J.P. Morgan Healthcare Conference.
- Note that the filing identifies ORIC common stock as trading on the Nasdaq Global Select Market under the symbol ORIC.